Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of a single injection of PTP-001 MOTYS in treating knee osteoarthritis OA in adults aged 40 to 80 years. This Phase 3, multicenter, randomized, double-blind, placebo-controlled trial compares PTP-001 to a placebo over a 52-week period in participants with mild to moderate knee OA confirmed by X-ray and symptoms. The goal is to assess improvements in knee function and pain over time. Participants will be randomly assigned to receive either a single 200 mg injection of PTP-001 or a placebo injection directly into the affected knee on Day 1. The study includes a screening period of up to 28 days before treatment, followed by the injection day and a 12-month follow-up phase to monitor outcomes. At least 260 participants will take part, split evenly between the two groups. Throughout the study, participants will attend scheduled visits for assessments including knee pain and function questionnaires, such as the WOMAC and PGA-OA scores, at 6, 9, and 12 months. Researchers will track improvements in knee symptoms and overall osteoarthritis status, as well as monitor safety and tolerability. Participants are expected to comply with study visits and restrictions, using only acetaminophen as needed for pain relief during the trial.
Actively Recruiting
Researchers are evaluating the effectiveness of zabalafin hydrogel in people aged 2 years and older who have mild to moderate atopic dermatitis, also known as eczema. This Phase 2b randomized, double-blind study includes two groups one with mild to moderate atopic dermatitis and another with the same condition plus a secondary skin infection. The study aims to compare zabalafin hydrogel to a placebo vehicle to understand its impact on eczema symptoms using a validated global assessment scale. Participants will be randomly assigned in a 21 ratio to receive either zabalafin 9.5% hydrogel or a placebo gel. The study treatment lasts 16 weeks following up to 2 weeks of screening. During treatment, participants will visit the clinic every 2 weeks for the first month and then monthly until the end of the study. The study evaluates not only the effectiveness but also the safety and tolerability of zabalafin compared to the placebo. Throughout the study, participants will undergo assessments including the validated Investigators Global Assessment, Eczema Area and Severity Index, pruritus itching rating, and patient-reported eczema measures. Safety monitoring and evaluation of antibacterial effects in those with skin infections are included. Participants must comply with study procedures, avoid using other topical products on the eczema lesions, and attend scheduled visits over the approximately 16-week treatment period.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.